BRAF and metastatic melanoma: In this section, our perspective is focused on 7c (Vemurafenib, PLX4032), an ATP-competitive RAF inhibitor containing azaindole scaffold, which was approved by the US FDA in 2011 for the treatment of patients with BRAF-V600E metastatic melanoma (Figure 7).